An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
| Autor: | Stein, Anthony S., Bajel, Ashish, Fleming, Shaun *, Jongen-Lavrencic, Mojca, Garciaz, Sylvain *, Maiti, Abhishek, Boissel, Nicolas, De Botton, Stephane *, Huls, Gerwin A., de Leeuw, David C. *, Avigan, David, Jensen, Kyle *, Demers, Brigitte *, Wagenaar, Timothy *, Mi, Gu *, Ziti-Ljajic, Samira *, Draganov, Dobrin *, Abbadessa, Giovanni, Wei, Andrew H |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:7476-7477 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|